FBInvestor
Stocks / Prelude Therapeutics Inc
Institutional Ownership

Prelude Therapeutics Inc

CUSIP 74065P101COMPRLDQ1 2026

13D / 13G Filings
27
Schedule 13D/13G on record
Beneficial Filers
9
Distinct reporting persons
Largest Stake
33.9%
Max % of class reported
Institutional Holders
52
13F filers (latest quarter)

Beneficial Owners — Schedule 13D / 13G

27 filings · latest Feb 13, 2026

Export CSV — Pro
#FiledReporting PersonForm% of ClassSharesFiling
1Feb 13, 2026Vaddi Krishna13G/A13.2%6.75MSEC
2Nov 7, 2025Incyte Corp13G9.9%4.37MSEC
3Jun 13, 2025Baker Bros. Advisors LP13D/A23.5%SEC
4May 15, 2025Vaddi Krishna13G/A13.8%6.40MSEC
5Feb 14, 2025Vaddi Krishna13G/A11.0%5.49MSEC
6Feb 13, 2025Deerfield Mgmt, L.P.13G/ASEC
7Feb 13, 2024Ubs Asset Management Americas Inc13G/ASEC
8Feb 12, 2024Flynn James E13G/A9.8%4.13MSEC
9Feb 12, 2024Vaddi Krishna13G/A11.1%4.91MSEC
10Jan 10, 2024Fmr LLC13G/A0.6%SEC

17 more beneficial-ownership filings on Premium

See the full Schedule 13D/13G history for Prelude Therapeutics Inc.

Unlock full history

Top Institutional Holders (13F)

Largest reported positions · latest quarter

View all →
#FundSharesValue
1Orbimed Advisors LLC10.91M$37.31M
2Baker Bros. Advisors LP10.12M$34.62M
3Kynam Capital Management, LP1.59M$5.45M
4Ecor1 Capital, LLC947.0K$3.24M
5Two Sigma Investments, LP923.6K$3.16M
6Sphera Funds Management Ltd.558.3K$1.91M
7Millennium Management LLC382.7K$1.31M
8Marshall Wace, LLP358.9K$1.23M
9Morgan Stanley322.2K$1.10M
10Blackrock, Inc.321.9K$1.10M